BSG and hepatocellular carcinoma: Systemic therapy is the mainstay of refractory HCC treatment, and ADC is a promising treatment strategy.[4] In this study, we developed an anti‐CD147 ADC, Mehozumab‐DM1, comprising a humanized CD147 antibody as the targeting component with the potent cytotoxic drug DM1 as the payload component, conjugated via SMCC, a non‐cleavable thioether linker.